Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).

Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).

Garcia, AM, Rezqallah-Arón, A, Duran-Lozano, L, López-Fernández, A, Darder, E, Alfonso, R, Cartró, M, Cruellas, M, Reig-Jané, J, Roqué, A, Tuset, N, Cajal, TRY, Brunet, J, Balmaña, J. Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants. EUROPEAN JOURNAL OF CANCER. 2026; 237DOI:10.1016/j.ejca.2026.116560. PMID:. IF:7.100(Q1/2D).

Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).

Martin-Broto, J, Strauss, SJ, Palmerini, E, Valverde, C, Sebio, A, Redondo, A, Stacchiotti, S, Grignani, G, Aliberti, S, Diaz-Beveridge, R, Billalabeitia, EG, Cruz, J, Carrasco-Garcia, I, Ibrahim, T, Diaz-Martin, J, Salguero-Aranda, C, Gutierrez, A, Mayordomo-Aranda, E, Ramos, R, Merino, J, Collini, P, Tirabosco, R, Bague, S, Romagosa, C, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer Communications. 2026; 46DOI:10.34133/cancomm.0015. PMID:41836677. IF:24.900(Q1/1D).

Holgado, A, Llansana, A, Vázquez, C, Gallego, O, Aguado, M, Valero, C, León, X. Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy. ORAL ONCOLOGY. 2026; 175DOI:10.1016/j.oraloncology.2026.107903. PMID:41722172. IF:3.900(Q1/2D).

Mezquita, L, Vicente-Herrero, MT, Cruz, P, de la Torre, MVRI, Hidalgo-Coloma, J, Garcia, LC, Gallego, O, Calvo, A, Martinez, K, Perez-Altozano, J, Molina, R, Garcia-Pardo, M, Gutierrez-Sainz, L, Moreno-Atahonero, E, Ore-Arce, M, Serrano, C, Terradillos-Garcia, MJ, Valero, MR, Reinoso-Barbero, L, Rodriguez, CA, Calvo-Cerrada, B. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04037-2. PMID:40956506. IF:2.500(Q3/6D).

Samsó, RH, Cabré, LC, Abós, SG, Solerdelcoll, MS, Majercakova, K, García, AS, Alegria, IG, Garrido, MF, Duarte, AM, López, JAG. Multidisciplinary Treatment of Inguinoscrotal Sarcomas: Analysis of 39 Cases Treated by Surgical Approach. Cancers. 2026; 18(5)DOI:10.3390/cancers18050876. PMID:41827809. IF:4.400(Q2/3D).

Portu, M, Balsa, M, Cotaina, M, Anguera, G, del Muro, XG, Algaba, F, Maroto, P. TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. Cancers. 2026; 18(6)DOI:10.3390/cancers18060958. PMID:41899560. IF:4.400(Q2/3D).

Garcia-Leon, Annabel, Mendoza, Julian I, Rueda, Ariana, Alba-Castellon, Lorena, Nomdedeu, Josep F, Gallardo, Alberto, Sierra, Jorge, Garrido, Ana, Vazquez, Esther, Villaverde, Antonio, Mangues, Ramon, Unzueta, Ugutz, Casanova, Isolda. Precision targeting of CXCR4+leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025; 192DOI:10.1016/j.biopha.2025.118573. PMID:. IF:(Q/D).

Parladé, E, García-Leon, A, Voltà-Durán, E, Unzueta, U, Mangues, R, Casanova, I, Villaverde, A, Váquez, E. Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2024; 202DOI:10.1016/j.ejpb.2024.114410. PMID:39004320. IF:4.300(Q1/2D).

Triguero, A, Pedraza, A, Perez-Encinas, M, Mata-Vazquez, MI, Velez, P, Fox, L, Gomez-Calafat, M, Garcia-Delgado, R, Gasior, M, Ferrer-Marin, F, Garcia-Gutierrez, V, Angona, A, Gomez-Casares, MT, Cuevas, B, Martinez, C, Perez, R, Raya, JM, Guerrero, L, Murillo, I, Bellosillo, B, Hernandez-Boluda, JC, Sanz, C, Alvarez-Larran, A. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (vol 101, 2231, 2022). ANNALS OF HEMATOLOGY. 2022; 101(12)DOI:10.1007/s00277-022-05005-4. PMID:36264368. IF:3.500(Q2/5D).

Fernández-Luis, S, Bermúdez, A, San Segundo, LY, González, MB, Asensio, SM, Esquirol, A, García-Cadenas, I, Pascual, MJ, Herruzo, B, Salas, MQ, Alburquerque-Prieto, C, Viguria-Alegría, MC, Pérez, A, Hernani, R, Mas, MH, Villalba, M, Calvo, CM, Fabbri, N, González-Rodriguez, AP, Bailén, R, Tomás, LG, Maño, LG, Salinas, AS, Calbacho, M, Bento, L, Balari, AS. Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular. TRANSPLANTATION. 2026; 110(1)DOI:10.1097/TP.0000000000005446. PMID:40524321. IF:5.000(Q1/1D).

Abrisqueta-Costa, P, García-Marco, JA, Gutiérrez, A, Hernández-Rivas, JA, Andreu-Lapiedra, R, Arguello-Tomas, M, Leiva-Farré, C, López-Roda, MD, Callejo-Mellén, A, Alvarez-García, E, Loscertales, J. Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study. Cancers. 2024; 16(23)DOI:10.3390/cancers16234004. PMID:39682190. IF:4.400(Q2/3D).

Nagler, A, Galimard, JE, Kayser, S, Kulagin, A, Blaise, D, Parovichnikova, E, Versluis, J, Itäla-Remes, M, Choi, G, Bufarull, RM, Sica, S, Roeven, MWH, von dem Borne, P, Bazarbachi, A, Sanz, J, Mohty, M, Ciceri, F. Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT. BONE MARROW TRANSPLANTATION. 2026; 61(1)DOI:10.1038/s41409-025-02726-8. PMID:41109900. IF:5.200(Q1/1D).

Madaro, L, Passafaro, M, Sala, D, Etxaniz, U, Lugarini, F, Proietti, D, Alfonsi, MV, Nicoletti, C, Gatto, S, De Bardi, M, Rojas-Garcia, R, Giordani, L, Marinelli, S, Pagliarini, V, Sette, C, Sacco, A, Puri, PL. Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis (vol 20, pg 917, 2018). NATURE CELL BIOLOGY. 2024; 26(3)DOI:10.1038/s41556-024-01365-3. PMID:38326555. IF:19.100(Q1/1D).

Fernández-Simón, E, Piñol-Jurado, P, Gokul-Nath, R, Unsworth, A, Alonso-Pérez, J, Schiava, M, Nascimento, A, Tasca, G, Queen, R, Cox, D, Suarez-Calvet, X, Díaz-Manera, J. Single cell RNA sequencing of human FAPs reveals different functional stages in Duchenne muscular dystrophy. Frontiers in Cell and Developmental Biology. 2024; 12DOI:10.3389/fcell.2024.1399319. PMID:39045456. IF:4.300(Q1/1D).

Ganoza, CA, Westenberger, A, Paul, JJ, Curado, F, Rennecke, J, Mannepalli, S, Zonic, E, Saravanakumar, D, Paknia, O, Al-Ali, R, Laabs, B, Csoti, I, Valzania, F, Vandenberghe, W, Reetz, K, Afshari, M, Hassin-Baer, S, Fonoff, ET, Gruber, D, de Rosa, A, Musacchio, T, Aguiar, PD, Negrotti, A, Tumas, V, Gomez-Esteban, JC, Gurevich, T, Pavese, N, Kulisevsky, J, Sammler, E, Klein, C, Bauer, P, Beetz, C. Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients. MOVEMENT DISORDERS. 2026; 41(4)DOI:10.1002/mds.70161. PMID:41439479. IF:7.600(Q1/1D).

Stocchi, F, Knecht, M, Marjanovic, I, Wach, A, Kopra, J, Kulisevsky, J. Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation. Neurology and Therapy. 2026; 15(3)DOI:10.1007/s40120-026-00898-z. PMID:41724884. IF:4.800(Q1/2D).

Valero-Bover, D, Monterde, D, Carot-Sans, G, Vela, E, González-Colom, R, Roca, J, Pontes, C, Michelena, X, Nogueras, MM, Aparicio, P, Corrales, I, Biec, T, Cano, I, Piera-Jiménez, J. Ten-year population-based assessment of multimorbidity burden progression in a regional cohort of 5.5 million adults. npj Digital Medicine. 2026; 9(1)DOI:10.1038/s41746-026-02395-x. PMID:41620560. IF:15.100(Q1/1D).